Montelukast Sodium Sandoz

Montelukast, the active ingredient in Montelukast Sodium Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is used to manage chronic asthma and allergic rhinitis in adults and children as part of a maintenance therapy regimen.

GNH USA supplies Montelukast Sodium Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Montelukast is indicated for conditions involving leukotriene‑mediated inflammation, primarily within the respiratory tract.

- Asthma: Improves long‑term control and reduces the frequency of asthma attacks when used as maintenance therapy. - Allergic rhinitis: Relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating therapy, consider the following safety measures.

- Neuropsychiatric monitoring: Observe patients for mood changes or suicidal ideation. - Hepatic function: Use cautiously in patients with liver impairment and monitor liver enzymes. - Hypersensitivity: Avoid in individuals with known allergy to montelukast or any excipients. - Pregnancy counseling: Discuss potential risks with pregnant or planning‑to‑be‑pregnant patients. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase montelukast plasma levels. - Rifampin: induces metabolism, potentially reducing efficacy. - Phenobarbital: enzyme inducer that can lower drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants: may augment neuropsychiatric side‑effects. - NSAIDs: concurrent use may increase risk of gastrointestinal discomfort.